



Credit: WHO/Neil Thomas.

## Next steps for the malaria vaccine for broader deployment

Mgaywa Magafu, WHO AFRO

# WHO welcomes historic investment by Gavi in the first malaria vaccine programme, December 2, 2021



Initial investment of US\$ 155.7 million for 2022-2025



OUR ALLIANCE

PROGRAMMES & IMPACT

INVESTING IN GAVI

#VACCINESWORK

NEWS & RESOURCES

Gavi Board approves funding to support malaria vaccine roll-out in sub-Saharan Africa



World Health Organization (WHO) @WHO

WHO welcomes a historic decision by @Gavi to invest in the first #malaria vaccine (RTS,S) - a great step forward in helping prevent malaria in children at risk [bit.ly/3EjgV8N](https://bit.ly/3EjgV8N)



THE GAVI BOARD HAS APPROVED A MALARIA VACCINATION PROGRAMME SET TO SAVE TENS OF THOUSANDS OF LIVES EVERY YEAR!


Gavi, the Vaccine Alliance

# Pilot countries: MoH-led phased introduction

Commitment to support continued vaccination in pilot areas




## Malawi




11 districts

## Ghana



81 districts in 7 regions

## Kenya



51 sub-counties in 8 counties

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Data Source: MoH Kenya; MoH Malawi; MoH Ghana. Map Production: WHO GIS Centre for Health, DNA/DDI. © WHO 2021. All rights reserved.




# UNICEF tender for malaria vaccines



UNICEF is seeking comprehensive and innovative proposals from developers and manufacturers of Malaria Vaccine for the sustained and uninterrupted supply of affordable Malaria Vaccine of assured quality, **starting from January 2023 through December 2026**, with possibility to extend the tender period by up to two additional years, through 2028.


- Bidders requested to submit proposal **for maximum available annual quantities**
- **All developers** of Malaria Vaccines anticipating to enter the Malaria Vaccine market during the tender period encouraged to submit their comprehensive proposals
- UNICEF will **consider innovative approaches to contracting**, such as volume-based commitments as well as any risk-sharing mechanisms for pricing proposed, provided they help achieve the objectives of this solicitation process.



# Why is a malaria vaccine allocation framework needed?




October 2021: WHO recommends the RTS,S/AS01 malaria vaccine be used for the prevention of *P. falciparum* malaria in children living in regions with moderate to high transmission as defined by WHO.



*Plasmodium falciparum* parasite prevalence (PfPR<sub>2-10</sub>) estimates, 2019

MVIP update 24 February 2022




## Intention of the Framework






**The Framework aims to offer guidance globally on the allocation of malaria vaccines between countries, and to offer high-level guidance nationally on the prioritization of areas for vaccination within countries (while respecting sovereign decision-making) while supply is limited.**

The expectation is that once finalized, all relevant stakeholders will adhere to the Framework, including malaria endemic countries, Gavi in its application guidance and processes for accessing and providing support; UNICEF in its procurement; the manufacturer(s), and other partners as they consider their financial and technical support to countries.

# Process for the development of the Malaria Vaccine Allocation Framework



## Draft Values framework (under development)

Governance principles	Ethical principles for allocation	Key considerations / side-constraints
<b>Transparency</b>  <b>Inclusiveness &amp; participation</b>  <b>Accountability</b>	<div><p><b>Greatest need:</b> Allocate the vaccine to those countries at greatest need</p><p><b>Maximize impact:</b> Allocate the vaccine in a way that will bring about the best health outcome – (achieve most health impact)</p><p><b>Equity (Equal Respect):</b> Prioritize countries that commit to fairness and addressing the needs of marginalized individuals and communities in their malaria vaccination programmes</p><p><b>As a tie-breaker - Reciprocity:</b> Allocate the vaccine in a way that honours the risks and burdens that individuals and groups have made in the past</p></div>	<div><p> Honour commitments to pilot countries</p><p> Ensure continuity / sustainability of access to vaccine once a programme has started</p><p> Avoid sub-optimal use of vaccine / minimize risk of vaccine wastage</p><p> Allocation should be mindful of what is operationally feasible to implement at country level</p><p> Allocation should not perpetuate pre-existing structural injustices</p></div>



# Consultation process



## *Governance principle: inclusiveness and participation*

- **Purpose:** orient, inform and create awareness on the situation and proposed global allocation process to **generate informed feedback** in an open, transparent and inclusive approach
- **Approach:** A series of webinar consultations, organized by stakeholder group, with option to provide written comments. **Summary of feedback provided to advisors to finalize Framework.**
  - Civil society organizations in affected areas: immunization and malaria CSOs and community representatives, country implementers (8 March)
  - Countries: EPI and NMCP managers in Africa, endemic countries in other regions, African health leaders and advisors (with break out groups) (9 March)
  - Global stakeholders: implementing partners, funders and advocacy groups (9 March)
- Guidance also being sought from AFRO RITAG (date TBC), SAGE (15 March) and MPAG (23 March)


## Key resources


The Malaria vaccine position paper – 04 March 2022

Malaria vaccine guidelines [online MAGICapp platform](#).

MVIP Bulletin ([Join the MVIP Distribution List](#))

- i. [Issue 1.Dec.2020](#)
- ii. [Issue 2.April.2021](#)
- iii. [Issue 3.September.2021](#)
- iv. [Issue 4. November 2021](#)





Questions?